US site closures as Takeda restructures vaccines business
This article was originally published in Scrip
Executive Summary
A fundamental restructuring of Takeda Pharmaceutical's vaccines operations will see the closure of three sites in the US as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.